Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
JAK1 Y654F Pyridone 6 Sezary's disease sensitive detail...
JAK1 Y654F Ruxolitinib Sezary's disease sensitive detail...
JAK1 Y654F JAK3 A573V Ruxolitinib Sezary's disease sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01871727 Phase III E7777 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Completed USA 2
NCT02542124 Phase II Interleukin-12 NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) Unknown status USA 0
NCT02581631 Phase Ib/II Brentuximab vedotin + Nivolumab A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) Unknown status USA | ITA | FRA | ESP | CAN 1
NCT02616965 Phase I Brentuximab vedotin + Romidepsin A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma Recruiting USA 0
NCT02953301 Phase II Resminostat Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN) Active, not recruiting ITA | FRA | ESP | DEU | BEL | AUT 6
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting USA 0
NCT03011814 Phase Ib/II Durvalumab Durvalumab + Lenalidomide Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Recruiting USA 0
NCT03063632 Phase II Interferon gamma + Pembrolizumab Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome Active, not recruiting USA 0
NCT03081910 Phase I CD5 CAR T cells Cyclophosphamide + Fludarabine Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) Recruiting USA 0
NCT03385226 Phase II Pembrolizumab A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (PORT) Recruiting 1
NCT03587844 Phase II Brentuximab vedotin Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients Recruiting USA 0
NCT03602157 Phase I ATLCAR.CD30.CCR4 cells Bendamustine + Fludarabine ATLCAR.CD30 cells + ATLCAR.CD30.CCR4 cells Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL Recruiting USA 0
NCT03695471 Phase II Pembrolizumab Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides Recruiting USA 0
NCT03902184 Phase II Gemcitabine + Lacutamab + Oxaliplatin Lacutamab IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK) Recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 1
NCT04185220 Phase I Mogamulizumab + rhIL-15 Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Active, not recruiting USA 0
NCT04217317 Phase II Bendamustine + CPI-613 CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT04234048 Phase I Fenretinide Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Not yet recruiting USA 0
NCT04256018 Phase II Mogamulizumab Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sezary Syndrome Recruiting USA 0
NCT04401020 Phase I SAR442257 First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL Recruiting USA | ESP 3
NCT04541017 Phase Ib/II Hu5F9-G4 Hu5F9-G4 + Mogamulizumab Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Suspended USA 0
NCT04652960 Phase I Duvelisib + Nivolumab Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome Recruiting USA 0
NCT04676087 Phase Ib/II Mogamulizumab Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides Recruiting USA 0
NCT04745234 Phase II Mogamulizumab Mogamulizumab Q4week Dosing in Participants With R/R CTCL Recruiting USA | ITA | FRA | ESP 1
NCT04752826 Phase Ib/II BI-1808 + Pembrolizumab BI-1808 BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20) Recruiting 4
NCT04930653 Phase II Mogamulizumab Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma Recruiting USA 0
NCT04960618 Phase II Gemcitabine + Pembrolizumab Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sezary Syndrome Recruiting USA 0